27 November 17.30-21.30
‘Toxin to Treatment – How naturally occurring toxic ingredients are being successfully used in patient therapies’
This event will be kindly hosted by Ipsen Bioinnovation at their Research and Development hub on Milton Park, Oxford. During the evening we will hear from a range of speakers who will give a broad insight into how naturally derived toxic ingredients are being developed to offer alternative treatments for a range of conditions and will share updates on recent research and development, regulatory matters, supply and commercialisation, and a look forward to the future potential of this area of drug discovery and treatment.
Keynotes will include:
John Chaddock, Vice President Neurology, Site Head at Ipsen Bioinnovation who have developed a technological platform for botulinum toxins and recombinant botulinum toxin technology.
Robin Carhart–Harris, Head of Psychedelic Research at Imperial College London, where he has conducted and overseen brain imaging studies of the effects of LSD, psilocybin, MDMA and DMT, plus a clinical trial of psilocybin for treatment-resistant depression.
Steve Trim, Founder of Venomtech whose custom molecular and therapeutic targeted arrays have been proven effective on hard-to-hit targets – offering new solutions where traditional approaches have failed.
Kevin Stephens, Managing Director of Agroceutical Products who are at the forefront in the production of sustainable quantities of naturally derived Galanthamine, a key active pharmaceutical ingredient approved for the treatment of Alzheimer’s disease.
Ekaterina Malievskaia, Co-Founder & Chief Scientific Officer of COMPASS Pathways, whose first major initiative is developing psilocybin therapy through late-stage clinical trials in Europe and North America for patients with treatment-resistant depression.
17:30 Registration and networking
18:00 Welcome & keynotes
19:30 Panel discussion and Q&A
20.10 Networking over drinks and nibbles
21:30 Evening close